Hudson Bay Capital Management
BLPH

Hudson Bay Capital Management’s Bellerophon Therapeutics, Inc. BLPH Stock Holding History

Hudson Bay Capital Management’s Portfolio BLPH Stock Details BLPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-23,809
Closed -$261K – 679
2020
Q1 		$261K Buy
+23,809
New +$160K 0.01% 395

Other funds holding BLPH

PCM
Puissance Capital Management New York $17.3M AUM 149.36% 1-Year Est. Return
NMVA
New Mountain Vantage Advisers New York $4.33B AUM 35.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TI
Telemetry Investments New York $63.3M AUM 0.06% 1-Year Est. Return
DC
Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Hudson Bay Capital Management's BLPH Position: Q2 2020 in Review

Hudson Bay Capital Management sold out of Bellerophon Therapeutics, Inc. (BLPH) in Q2 2020, closing a stake of 23,809 shares — an estimated $261K sold.

Hudson Bay Capital Management first reported a position in BLPH in Q1 2020 and held it in 1 quarter. The position peaked at $261K in Q1 2020. 37 funds tracked by Wall St. Rank hold BLPH as of Q2 2020.

  • Hudson Bay Capital Management reported no remaining Bellerophon Therapeutics, Inc. position as of Q2 2020 after selling out during the quarter.
  • Hudson Bay Capital Management sold 23,809 Bellerophon Therapeutics, Inc. shares in Q2 2020, an estimated $261K.
  • Hudson Bay Capital Management first reported a position in Bellerophon Therapeutics, Inc. in Q1 2020 and held it in 1 quarter.
  • Hudson Bay Capital Management's Bellerophon Therapeutics, Inc. position peaked at $261K in Q1 2020.
  • 37 funds tracked by Wall St. Rank held Bellerophon Therapeutics, Inc. as of Q2 2020.

Based on Hudson Bay Capital Management's 13F filing for Q2 2020, filed 12 Aug 2020.